PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33707301-1 2021 Combined neprilysin (NEP) inhibition (sacubitril) and angiotensin type 1 receptor (AT1R) antagonism (valsartan) is used in the treatment of congestive heart failure and is gaining interest for other angiotensin II (AngII)-related cardiovascular diseases. Valsartan 101-110 angiotensin II, type I receptor-associated protein Mus musculus 54-81 33707301-1 2021 Combined neprilysin (NEP) inhibition (sacubitril) and angiotensin type 1 receptor (AT1R) antagonism (valsartan) is used in the treatment of congestive heart failure and is gaining interest for other angiotensin II (AngII)-related cardiovascular diseases. Valsartan 101-110 angiotensin II, type I receptor-associated protein Mus musculus 83-87 29674000-8 2018 The AT1R blocker valsartan (40 mg/kg/day), but not the calcium channel blocker amlodipine (5 or 10 mg/kg/day), significantly suppressed the effect of Ang II. Valsartan 17-26 angiotensin II, type I receptor-associated protein Mus musculus 4-8 33636353-4 2021 Here, we investigated potential new BDK inhibitors and discovered valsartan, an angiotensin II type 1 receptor (AT1R) blocker, as a new BDK inhibitor. Valsartan 66-75 angiotensin II, type I receptor-associated protein Mus musculus 80-110 33636353-4 2021 Here, we investigated potential new BDK inhibitors and discovered valsartan, an angiotensin II type 1 receptor (AT1R) blocker, as a new BDK inhibitor. Valsartan 66-75 angiotensin II, type I receptor-associated protein Mus musculus 112-116 24662196-4 2014 Light-exposed Balb/c mice that were treated with the AT1R blockers (angiotensin II receptor blockers; ARBs) valsartan, losartan, and candesartan before and after the light exposure exhibited attenuated visual function impairment, compared to vehicle-treated mice. Valsartan 108-117 angiotensin II, type I receptor-associated protein Mus musculus 53-57 25485905-6 2015 The increase in endothelial reactive oxygen species in response to elevated PTM was reduced by the ANG II type 1 receptor (AT1R) antagonists losartan (3 muM) or valsartan (1 muM). Valsartan 161-170 angiotensin II, type I receptor-associated protein Mus musculus 123-127 27102209-10 2016 Both effects were significantly blocked by valsartan, which inhibits angiotensin II type 1 receptor. Valsartan 43-52 angiotensin II, type I receptor-associated protein Mus musculus 69-99 26672616-7 2016 The angiotensin II type 1 receptor (AT1R) blocker valsartan or renin inhibitor aliskiren dramatically suppressed PA-induced upregulation of BiP, CHOP, IRE1alpha, p-eIF2alpha, and ATF4 in HK2 cells. Valsartan 50-59 angiotensin II, type I receptor-associated protein Mus musculus 4-34 26672616-7 2016 The angiotensin II type 1 receptor (AT1R) blocker valsartan or renin inhibitor aliskiren dramatically suppressed PA-induced upregulation of BiP, CHOP, IRE1alpha, p-eIF2alpha, and ATF4 in HK2 cells. Valsartan 50-59 angiotensin II, type I receptor-associated protein Mus musculus 36-40 21987107-10 2011 Both AL and VA reduced myocardial AT1R levels, without affecting AT2R levels, and increased the expression of Sirt1 and PGC-1alpha with increased phosphorylation of Akt and eNOS. Valsartan 12-14 angiotensin II, type I receptor-associated protein Mus musculus 34-38 22805546-9 2013 Valsartan (AT1R antagonist) but not PD123319 (AT2R antagonist) treatment attenuated the AngII-induced promotion of VEGF synthesis by BMSCs. Valsartan 0-9 angiotensin II, type I receptor-associated protein Mus musculus 11-15 18787107-2 2008 Valsartan [N-(1-oxopentyl)-N-[[2"-(1H-tetrazol-5-yl)[1,1"-biphenyl]-4-yl]methyl]-l-valine] is an antagonist of the angiotensin II type 1 receptor (AT1R) that reduces the incidence of type 2 diabetes mellitus. Valsartan 0-9 angiotensin II, type I receptor-associated protein Mus musculus 115-145 20136508-3 2010 Daily oral administration of valsartan or enalapril at 10 mg/kg/day to db/db mice for 6 weeks reversed the blunted acetylcholine-induced endothelium-dependent dilatations, suppressed the upregulated expression of angiotensin II type 1 receptor (AT(1)R) and NAD(P)H oxidase subunits (p22(phox) and p47(phox)), and reduced reactive oxygen species (ROS) production. Valsartan 29-38 angiotensin II, type I receptor-associated protein Mus musculus 213-243 20136508-3 2010 Daily oral administration of valsartan or enalapril at 10 mg/kg/day to db/db mice for 6 weeks reversed the blunted acetylcholine-induced endothelium-dependent dilatations, suppressed the upregulated expression of angiotensin II type 1 receptor (AT(1)R) and NAD(P)H oxidase subunits (p22(phox) and p47(phox)), and reduced reactive oxygen species (ROS) production. Valsartan 29-38 angiotensin II, type I receptor-associated protein Mus musculus 245-251 20100990-3 2010 We examined the hypothesis that the AT1R blocker valsartan reduces the metabolic consequences and inflammatory effects of a high-fat (Western) diet in mice. Valsartan 49-58 angiotensin II, type I receptor-associated protein Mus musculus 36-40 20100990-9 2010 In isolated adipocytes, valsartan treatment blocked or attenuated Western diet-induced changes in expression of several key inflammatory signals: interleukin 12p40, interleukin 12p35, tumor necrosis factor-alpha, interferon-gamma, adiponectin, platelet 12-lipoxygenase, collagen 6, inducible NO synthase, and AT1R. Valsartan 24-33 angiotensin II, type I receptor-associated protein Mus musculus 309-313 20100990-10 2010 Our findings indicate that AT1R blockade with valsartan attenuated several deleterious effects of the Western diet at the systemic and local levels in islets and adipose tissue. Valsartan 46-55 angiotensin II, type I receptor-associated protein Mus musculus 27-31 18787107-2 2008 Valsartan [N-(1-oxopentyl)-N-[[2"-(1H-tetrazol-5-yl)[1,1"-biphenyl]-4-yl]methyl]-l-valine] is an antagonist of the angiotensin II type 1 receptor (AT1R) that reduces the incidence of type 2 diabetes mellitus. Valsartan 0-9 angiotensin II, type I receptor-associated protein Mus musculus 147-151 18327089-6 2008 By contrast, pharmacological inhibition of angiotensin II type 1 receptor (AT1R) with valsartan reduced the degree of renal fibrosis and the number of fibrocytes in both the kidney and the bone marrow. Valsartan 86-95 angiotensin II, type I receptor-associated protein Mus musculus 43-73 18327089-6 2008 By contrast, pharmacological inhibition of angiotensin II type 1 receptor (AT1R) with valsartan reduced the degree of renal fibrosis and the number of fibrocytes in both the kidney and the bone marrow. Valsartan 86-95 angiotensin II, type I receptor-associated protein Mus musculus 75-79 34697992-4 2021 The AT1R antagonist Valsartan is commonly prescribed to control high blood pressure, heart failure, and diabetic kidney diseases. Valsartan 20-29 angiotensin II, type I receptor-associated protein Mus musculus 4-8